Please select an option below to help us tailor your newsletter to best suit your content interests!
Axel Grothey, MD The New England Journal of Medicine (NEJM) has recently published an editorial entitled “Pembrolizumab as first-line therapy in mismatch repair-deficient advanced colorectal cancer: A new standard of care” written by West Cancer Center’s GI Medical Oncology Lead and GI Oncology Clinical Research Director, Dr. Axel Grothey. Click the link below… Read more »
Matching patient populations with a targetable genomic alteration to a specific investigational study is the aim of a new clinical trial through OneR and Genentech. This partnership will facilitate collaborations on various clinical trials, scientific research and real-world data studies that will advance personalized cancer care at community oncology centers like West. “With too many… Read more »
West Clinic Offering New, Safer Radiation Therapy Options for Prostate Cancer Patients Prostate cancer is the most common cancer in American men, with more than 183,000 new cases diagnosed each year. More than 60,000 American men opt to treat their prostate cancer with radiation every year, but because of the proximity of the rectum… Read more »
West Clinic Offers Patients Even More Oncology Treatment Options West joins launch of new technology platform, OneR, to increase trial therapies for patients As an affiliate of OneOncology, West Clinic now has the ability to further its clinical trial offerings and oncology research knowledge by joining the launch of OneR. OneR is a… Read more »
The 5th Annual West Oncology Conference at Graceland: Advances in the Business and Science of Oncology Special Updates from COA, ASCO, ASH, ASTRO, and ESMO was a valuable forum for the presentation and discussion of new research findings. Participants were provided with an update on practice-changing data on women’s cancers, genitourinary malignancies, disparities in cancer… Read more »
Targeted treatments ‘moving the bar’ in metastatic breast cancer Research exploring novel targeted agents for patients with metastatic breast cancer is mounting and spurring excitement in the oncology field. “There really is a lot to be excited about,” Gregory A. Vidal, MD, PhD, medical oncologist at West Cancer Center and Research Institute and associate professor in… Read more »
Abstract The phosphatidylinositol-3-kinase (PI3K) pathway is frequently dysregulated in human breast cancer. Approximately 30%of all patients with breast cancer will carry mutations of the PIK3CA gene, which encodes the PI3K catalytic subunit isoform p110a. Mutations in PIK3CA have been associated with resistance to endocrine therapy, HER2-directed therapy, and cytotoxic therapy. Early trials of pan-PI3K inhibitors… Read more »
“We really believe that biosimilars line up as a value accretion for every constituency, whether it’s the patient, the practice, or the payer,” said Lee Schwartzberg, MD, FACP, executive director, West Cancer Center. Click here for full article & video interview. Transcript: OneOncology announced that its practices have begun administering the 2 cancer… Read more »
In 2016, I was diagnosed with Stage 1 breast cancer. And I was, on one level, lucky. Lucky that, after not bothering to get a mammogram since 2011, I didn’t discover a tumor that had spread to other parts of my body. “After four years of not being screened, that is a blessing,” said Keesha… Read more »
West Cancer Center – Methodist Le Bonheur Healthcare Would like to invite you to attend Thriving Together: Living Beyond Metastatic Breast Cancer! Monday, July 31, 2017, 6 p.m. – 8 p.m West Cancer Center 7945 Wolf River Blvd Germantown, TN 38138 Our Keynote Speaker & Program will begin at 7:15 p.m. on… Read more »